The preliminary data presented here support the idea that GSNOR inhibition may be more beneficial in asthmatic patients with a type 2 inflammatory phenotype associated with eosinophils than those studied in this initial clinical trial and warrant further investigation of GSNOR inhibition in a selected population with more‐severe asthma. Here, ADH5 is linked to asthma.